Here are two articles with the details
From CIDRAP - Center for Infectious Disease Research & Policy, University of Minnesota
When confusion replaces clarity about vaccines, children
pay the price
Michael T. Osterholm, PhD, MPH and Sarah Despres
When the US government changes long-standing childhood vaccine recommendations, parents deserve clarity: what changed, why it changed, and what it means for their children’s health. Instead, the recent revamp of the US childhood immunization schedule was announced abruptly by the Department of Health and Human Services (HHS) with limited explanation and evidence, and little transparency about how decisions were reached or how they are expected to improve health outcomes.![]() |
| Who needs science? |
Much of the public commentary since the announcement has
focused on the remaining policy levers available to HHS to reduce access to
vaccines, such as changes to insurance coverage, liability protections, or
federal programs for under- and uninsured children. Those concerns are real.
But they obscure a more immediate and troubling reality: vaccine uptake is declining,
not because access has disappeared, but because vaccination itself is being
steadily de-normalized through uncertainty, mixed messages, and the spread of
inaccurate information coming from the political appointees at HHS.
HHS Secretary Robert F. Kennedy Jr. achieved his intended goal. He created even more confusion about and distrust in the use of vaccines.
In an environment already saturated with inaccurate information, silence or ambiguity can be as damaging as falsehoods. When official health guidance lacks transparency and consistency, inaccuracies fill the vacuum.
Real consequences from unclear guidance
HHS’s restructuring of the childhood immunization schedule
illustrates the problem. A single, clear set of routine recommendations was
replaced with a complicated three-tiered framework: routine vaccination,
vaccination for high-risk children, and vaccination based on “shared clinical
decision-making.” For parents already navigating an overwhelming volume of
health information, this approach introduces ambiguity where clarity is
paramount. And the accompanying documents, including a decision memo and assessment, did
little to explain the rationale for the changes or demonstrate how they would
improve health outcomes.
Confusion of this kind has predictable effects: When parents
are uncertain, many delay. Some opt out entirely. And as vaccination rates
fall, preventable diseases return.
HHS has widely circulated accusations about vaccine risks
without accompanying data, corrections, or context, and we are already seeing
the consequences with decreasing pediatric
vaccination rates and an increase in life-threating
diseases.
For example, pertussis (whooping cough)
outbreaks are increasing, putting infants who are too young to be fully
vaccinated at particular risk. Outpatient visits for respiratory or “flu-like”
illness are at their highest in nearly 30 years, and 32 children have died this
season after contracting influenza, according to the latest FluView report from
the Centers for Disease Control and Prevention. And measles, which was
officially eliminated from the United States in 2000, is making a comeback, with 2,242 cases reported
in 2025, and 171 cases reported in the first two weeks of 2026.
These are not failures of modern medicine; they are the
result of elected officials, those who lead our federal health agencies, sowing
confusion and raising doubt about vaccines’ safety and effectiveness. Now,
their plans are expanding, with efforts to fund questionable research that
seems designed to yield predetermined outcomes under way in Africa.
Crucial next steps
So, what can be done?
First, the country needs renewed investment in large-scale
public education about vaccination as disease prevention. Effective public
health campaigns require research, message testing, community-level outreach,
and evaluation. They are expensive and resource-intensive, but they work.
Government alone cannot shoulder this responsibility; philanthropy and private
partners can play an essential role.
Second, professional and non-governmental organizations must
continue to provide clear, evidence-based guidance. Medical societies (e.g.,
the American Academy of Pediatrics) and
independent groups (e.g., the Vaccine Integrity Project) are
stepping in to synthesize data and communicate what is known about vaccine
safety and effectiveness. This work helps parents and clinicians make informed
decisions in the absence of federal clarity.
Third, the media can better serve the public by centering
coverage on health impacts rather than on procedural changes alone. Reporting
on disease outbreaks, hospitalizations, and pediatric deaths alongside
explanations of how vaccination prevents them helps ground abstract policy
shifts in reality. Scrutiny should focus not just on what recommendations
changed, but on whether the evidence supporting those changes has been made
public, a practice that has been in place for decades.
Finally, Congress has a responsibility to ensure sustained
funding for immunization programs and to insist on transparency, rigor, and
accountability from federal health agencies, standards that should apply
regardless of who is in leadership.
Vaccines remain one of the most effective tools in modern
medicine. When they are undermined, not through bans or shortages, but through
confusion and doubt, the harm is quiet at first, then unmistakable. The
question before us is not whether vaccination still works. It is whether we
will communicate its value clearly enough, consistently enough, and responsibly
enough to protect the children who depend on us to get this right.
Dr Michael Osterholm is director of the Center for
Infectious Disease Research and Policy at the University of Minnesota and is
executive director of the Vaccine Integrity Project.
Sarah Despres is a public health policy expert who
serves on the Vaccine Integrity Project’s Board of Advisers.
Fewer older adults being
vaccinated against flu, pneumonia, CDC data reveal
The proportions of older US adults vaccinated against
influenza in the previous year and those ever vaccinated against pneumonia were
lower in 2024 than in 2019, according to a report published today by the
Centers for Disease Control and Prevention’s (CDC’s) National Center for Health
Statistics.
The authors used 2024 National Health Interview Survey
responses to estimate the percentage of adults aged 65 years and older who
received the flu and/or pneumonia vaccines by temporal trends and
sociodemographic factors.
“Older adults face higher risks of certain diseases because
immune systems tend to weaken with age, and they also are more likely to have
other underlying health conditions,” they wrote. “The majority of deaths from
flu and pneumonia occur in adults age 65 and older.”
Differences by age-group, race
The percentages of older adults who received a flu vaccine
in 2023 and who ever were vaccinated against pneumonia were lower in 2024
(67.1% and 64.7%, respectively) than in 2019 (70.5% and 67.0%,
respectively). Rates of flu vaccine uptake were comparable in men (67.9%)
and women (66.3%).
Flu vaccination rates were lowest among adults aged 65 to 74
years (62.6%) and higher among those aged 75 to 84 (71.9%) and 85 and older
(75.3%). The proportion of older adults who ever received a pneumonia
vaccine was 64.7% and was higher in women (66.7%) than in men (62.2%).
The majority of deaths from flu and pneumonia occur in
adults age 65 and older.
White adults were more likely to have received a flu vaccine
(68.0%) than those who were Black (63.2%) or Hispanic (61.7%). The proportion
vaccinated against flu rose with increasing family income as a percentage of
the federal poverty level (FPL), from 57.9% in people with incomes less than
100% FPL to 73.6% in those with incomes of 400% FPL or higher.
For pneumonia, women (66.7%) were more likely than men
(62.2%) to have gotten vaccinated. Adults aged 65 to 74 years (57.9%) were less
likely than those aged 75 to 84 (73.8%) or 85 and older (71.2%) to have done
so.
White adults were more likely than their Black or Hispanic
peers ever to have had a pneumonia vaccine (68.3% vs 54.6% vs 48.6%,
respectively). The proportion of adults aged 65 and older who ever received a
pneumonia vaccine climbed with increasing family income, from 51.1% in those
with incomes less than 100% FPL to 70.3% in those with incomes of 400% FPL or
more.

